Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Subscribe To Our Newsletter & Stay Updated
